2016 Volume 34 Issue 1 Pages 22-25
On the clinical management of neurodegenerative dementia including Alzheimer's disease (AD), molecular imaging using positron emission topography (PET), which makes it possible to detect in vivo pathological modification in the brain, have been developed. While amyloid PET imaging implies an important role for diagnosis of AD, tau PET imaging also would be useful as a biomarker to diagnose tauopathies including non-AD dementia as well as to evaluate disease severity.